Rapport Therapeutics (NASDAQ:RAPP) Trading Down 7.2% - What's Next?

Key Points

• Rapport Therapeutics shares fell 7.2% to about $38.47, with trading volume down 95% from the average; the stock is down 15.3% according to the article’s trading update.
• Analyst sentiment remains broadly positive, with a consensus “Buy” rating and an average price target of $66.25, including UBS’s $80 target. However, the company recently missed quarterly EPS expectations, reporting a loss of $1.19 per share versus the $1.12 expected.
• CEO Abraham Ceesay sold 28,958 shares at an average price of $48.01, while insiders sold 81,244 shares worth roughly $3.86 million over the past three months. Several major institutions, including BlackRock, Johnson & Johnson, and ARCH Venture Management, recently acquired stakes.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report)'s stock price was down 7.2% during trading on Wednesday . The stock traded as low as $39.14 and last traded at $38.4660. 16,386 shares were traded during mid-day trading, a decline of 95% from the average daily volume of 346,907 shares. The stock had previously closed at $41.47.

Wall Street Analysts Forecast Growth

RAPP has been the topic of several analyst reports. UBS Group set a $80.00 price target on shares of Rapport Therapeutics in a report on Wednesday. Raymond James Financial restated a "strong-buy" rating on shares of Rapport Therapeutics in a research note on Tuesday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Rapport Therapeutics in a report on Friday, July 17th. William Blair started coverage on Rapport Therapeutics in a report on Tuesday, July 28th. They set an "outperform" rating on the stock. Finally, Leerink Partners assumed coverage on Rapport Therapeutics in a research report on Wednesday, June 24th. They issued an "outperform" rating and a $52.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $66.25.

Rapport Therapeutics Trading Down 15.3%

The company's 50 day moving average is $44.84 and its 200 day moving average is $38.79. The company has a market cap of $1.68 billion, a PE ratio of -11.57 and a beta of 1.02.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.07). Analysts expect that Rapport Therapeutics, Inc. will post -4.09 EPS for the current year.

Insider Transactions at Rapport Therapeutics

In other news, CEO Abraham Ceesay sold 28,958 shares of the firm's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $48.01, for a total transaction of $1,390,273.58. Following the sale, the chief executive officer directly owned 486,108 shares in the company, valued at $23,338,045.08. This trade represents a 5.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 81,244 shares of company stock valued at $3,858,615 over the last three months. Insiders own 12.48% of the company's stock.

Hedge Funds Weigh In On Rapport Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. TRV GP V LLC acquired a new position in shares of Rapport Therapeutics in the 2nd quarter worth approximately $261,709,477. ARCH Venture Management LLC acquired a new position in Rapport Therapeutics during the 2nd quarter worth about $155,376,512. Goldman Sachs Group Inc. boosted its holdings in Rapport Therapeutics by 23.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 3,001,879 shares of the company's stock valued at $91,077,000 after acquiring an additional 579,903 shares during the period. BlackRock Inc. acquired a new position in Rapport Therapeutics in the 2nd quarter valued at about $112,500,000. Finally, Johnson & Johnson purchased a new stake in Rapport Therapeutics during the second quarter worth about $74,360,823.

About Rapport Therapeutics

Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for disorders of the central nervous system. The company's research centers on receptor-associated proteins, which help regulate neurotransmitter receptors and may provide opportunities to develop more selective therapies than those that target receptors broadly.

Rapport's lead development program, RAP-219, is an orally administered investigational therapy designed to modulate AMPA receptors through their associated proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.